Hyperhomocysteinemia in Myelodysplastic Syndromes: Specific Association with Autoimmunity and Cardiovascular Disease

Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Marina Motta(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Fabrizia Bamonti-catena(Ospedale Maggiore), Giuliana Cighetti, Nicola Stefano Fracchiolla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), M Carrabba(Luigi Sacco Hospital), Viviana Cavalca(Centro Cardiologico Monzino), Anna Teresa Maiolo(Ospedale Maggiore)
Leukemia & lymphoma/Leukemia and lymphoma
January 1, 2001
10.3109/10428190109057963
Cited by 9

Related Papers

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272